- Astellas Pharma‘s operating income for the financial year is forecasted at 48.00 billion yen, which is below the estimated 175.17 billion yen.
- The projected net income is 30.00 billion yen, below the estimated 126.84 billion yen.
- Net sales are predicted to reach 1.65 trillion yen, slightly less than the estimated 1.67 trillion yen.
- The estimated dividend yield is 74.00 yen, just below the estimate of 74.60 yen.
- The company reported a fourth quarter operating loss of 48.60 billion yen, marking a 0.7% year on year increase. It had been estimated to turn a profit of 14.55 billion yen.
- Prograf sales reached 203.09 billion yen this year, exceeding the 200.03 billion yen estimate with a 2.2% year on year increase.
- Sales of Betanis/Myrabetriq/Betmiga increased by 5% year on year to 198.07 billion yen, exceeding the estimate of 192.83 billion yen.
- Xtandi sales rose 14% year on year to 750.47 billion yen, surpassing the estimate of 726.42 billion yen.
- Astellas Pharma currently holds 11 buys, 5 holds, and 1 sell in the market.
“`
Note: Do not include any virtual meeting dial-in information. Do not use any sources besides the original company disclosures for the information provided for this listicle.
Astellas Pharma on Smartkarma
Analyst coverage on Astellas Pharma by Tina Banerjee on Smartkarma presents a contrasting view of the company’s recent performance. In a bullish report titled “Astellas Pharma (4503 JP): Some Recent Positive Developments That Will Yield Benefit in Long-Run,” Banerjee highlights Astellas’ positive developments, such as the European approval of the potential blockbuster drug Veoza and the acquisition of Propella Therapeutics. These steps are seen as pivotal for Astellas’ long-term growth prospects.
However, in a bearish report titled “Astellas Pharma (4503 JP): Underwhelming H1 Result; Massive Cut in FY24 Profit Guidance,” Banerjee expresses concerns over Astellas’ H1FY24 performance, with minimal revenue growth and significant declines in operating and net profit. Factors such as generic competition and increased expenses led to a downward revision of profit forecasts for FY24 by more than 50%. This mixed coverage underscores the importance of closely monitoring Astellas Pharma‘s strategic moves and financial performance.
A look at Astellas Pharma Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 3 | |
Dividend | 5 | |
Growth | 2 | |
Resilience | 2 | |
Momentum | 2 | |
OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Astellas Pharma Inc. has a promising long-term outlook based on its overall scores. The company scored high in dividend stability with a score of 5, indicating a strong dividend performance. This suggests that Astellas Pharma provides reliable returns to its investors through regular dividend payments. However, the company scored lower in growth potential, resilience, and momentum, with scores of 2 for each factor. This implies that while Astellas Pharma may lack strong growth prospects, it maintains a stable position in the market and is not experiencing significant momentum.
As a pharmaceutical company focusing on various therapeutic fields such as Urology, Immunology, Oncology, Neuroscience, and others, Astellas Pharma with its global workforce of over 17,000 employees is dedicated to researching, developing, and marketing prescription drugs worldwide. While the company’s strong dividend performance is a positive indicator for investors, its lower scores in growth, resilience, and momentum suggest a need for strategic planning to capitalize on market opportunities and overcome challenges in the competitive pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars